Mergers & acquisitions
Cullinan and Taiho announced that Taiho was acquiring Cullinan Pearl and will co-develop and co-commercialize their non-small cell lung cancer drug.
Cortexyme has entered into a deal to acquire Novosteo. Once the deal is finalized, the companies will enter the rare disease space and operate under the name Quince Therapeutics.
Pfizer made the splash of the young week Tuesday morning, inking an acquisition deal with New Haven, Connecticut-based Biohaven Pharma totaling $11.6 billion.
Could big pharma buy out much of the biotech industry? Yes, according to analysts. But that’s not likely to happen anytime soon.
Zymeworks received an unsolicited, non-binding acquisition offer from global investment firm All Blue Capital. All Blue is offering $10.50 per share for a total of $773 million in cash.
Although treating patients is the top priority of the biopharma industry, there’s no doubt that money is the driver. This is a broad look at the current state of biopharma bucks.
Coeptis Therapeutics is merging with special purpose acquisition company Bull Horn Holdings in a definitive deal worth around $175 million.
Regeneron announced it has acquired Checkmate Pharmaceuticals and that it has entered a clinical trial collaboration with SpringWorks Therapeutics to treat multiple myeloma.
Ubix Therapeutics has announced a collaboration agreement with SK Biopharmaceuticals, and Engitix and Takeda are teaming up to develop a therapeutic for fibrostenotic IBD.
GSK is acquiring Sierra Oncology for $1.9 billion in a deal expected to help both companies take a major step in developing a treatment for rare types of cancer.
PRESS RELEASES